Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker XGN
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Jorey Chernett 10% owner | XGN Exagen Inc. | Sale | 58,068 | $4.08 | $236.9K Sale | Form 4 ↗ |
| Nov 12, 2026 | Jorey Chernett 10% owner | XGN Exagen Inc. | Sale | 109,436 | $4.65 | $508.9K Sale | Form 4 ↗ |
| Nov 11, 2026 | Jorey Chernett 10% owner | XGN Exagen Inc. | Buy | 71,315 | $5.23 | $373.0K Buy | Form 4 ↗ |
| Nov 10, 2026 | Jorey Chernett 10% owner | XGN Exagen Inc. | Buy | 7,085 | $5.26 | $37.3K Buy | Form 4 ↗ |
| Nov 9, 2026 | Jorey Chernett 10% owner | XGN Exagen Inc. | Buy | 8,500 | $6.35 | $54.0K Buy | Form 4 ↗ |
| Nov 6, 2026 | Jorey Chernett 10% owner | XGN Exagen Inc. | Sale | 11,265 | $6.14 | $69.2K Sale | Form 4 ↗ |
| Oct 19, 2026 | Jorey Chernett 10% owner | XGN Exagen Inc. | Buy | 14,000 | $7.46 | $104.4K Buy | Form 4 ↗ |
| Oct 16, 2026 | John Aballi President and CEO, Director | XGN Exagen Inc. | Sale | 34,294 | $7.87 | $269.8K Sale | Form 4 ↗ |
| Sep 1, 2026 | Jeffrey G. Black Chief Financial Officer | XGN Exagen Inc. | Sale | 20,614 | $7.22 | $148.8K Sale | Form 4 ↗ |
| Mar 3, 2026 | John Aballi President and CEO, Director | XGN Exagen Inc. | Sale | 15,698 | $3.62 | $56.8K Sale | Form 4 ↗ |
| Feb 24, 2026 | John Aballi President and CEO, Director | XGN Exagen Inc. | Sale | 11,430 | $3.61 | $41.3K Sale | Form 4 ↗ |
| Feb 24, 2026 | Jeffrey G. Black Chief Financial Officer | XGN Exagen Inc. | Sale | 1,584 | $3.61 | $5,718 Sale | Form 4 ↗ |
| Oct 16, 2025 | John Aballi President and CEO, Director | XGN Exagen Inc. | Sale | 31,787 | $11.82 | $375.7K Sale | Form 4 ↗ |
| Sep 2, 2025 | Jeffrey G. Black Chief Financial Officer | XGN Exagen Inc. | Sale | 20,466 | $9.79 | $200.4K Sale | Form 4 ↗ |
| Mar 25, 2025 | NMSIC Co-Investment Fund, L.P. 10% owner | XGN Exagen Inc. | Sale | 350,000 | $3.30 | $1.2M Sale | Form 4 ↗ |
| Nov 20, 2024 | Sun Mountain Capital Partners LLC 10% owner | XGN Exagen Inc. | Sale | 200,000 | $3.30 | $660.0K Sale | Form 4 ↗ |
| Nov 15, 2024 | Jeffrey G. Black Chief Financial Officer | XGN Exagen Inc. | Buy | 22,298 | $2.98 | $66.4K Buy | Form 4 ↗ |
17 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances